Article | February 18, 2022

Lyophilized Products Are On The Rise: What You Need To Know

Source: Emergent CDMO
GettyImages-1316775813-vial-production

When Spine BioPharma was looking for support in redeveloping and manufacturing a drug product recently, they found a partner in Emergent BioSolutions. As a contract development manufacturing organization (CDMO), Emergent would be able to quickly ramp up production of the drug at hand, and it would also be able to convert it to a form that would make it stable at room temperature, through a process called lyophilization. That process—also known as freeze-drying—would, in turn, simplify logistics for shipping and storage.

Spine BioPharma is just one of many biopharmaceutical organizations seeking assistance in the lyophilization process, which is growing in popularity. According to a report by MarketsandMarkets, the global freeze-drying/lyophilization equipment market is expected to reach $7.3 billion by 2025—from $4.9 billion in 2020—at a CAGR of 8.2%.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online